Biovest International, Inc. (PINK:BVTI) gains furiously these days. Yesterday, the stock added the next 16.67% to its price 
and its traded volume jumped up.
Historical data shows that the climb started on Jan 19, when Biovest reported it had been granted Small and Medium Sized Enterprise by the European Medicines Agency. Being released, the news immediately pushed up BVTI stock price and the uptrend is still on.
Biovest International is a biotechnology company focusing primarily on the development of BiovaxID, a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkins lymphoma, or follicular NHL. On Tuesday, the company invited its stockholders to the Annual Meeting which will be held on March 7 this year.
In addition, the Board of Directors recommended the stockholders to approve an amendment to the company’s Amended and Restated Certificate of Incorporation to increase the number of shares of common stock and to correspondingly increase the overall number of shares of capital stock that the company is authorized to issue. Though, the voting results are still to be seen.[BANNER]
Meanwhile, the biggest issue for Biovest appears to be its financials. The company’s annual report shows that revenues have decreased, while the losses flew up and the stockholders’ deficit remained a negative value.
Having in mind these facts plus the numerous rick factors listed in the company’s 10-K, it turns out that investing in BVTI should be carefully reconsidered.
